Resonance Health Ltd
- Country
- Ownership
- -
- Employees
- 18
- Market Cap
- -
- Introduction
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Clinical Trials
1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
Resonance Health Secures $13.775 Million Clinical Trial Contract with Sun Pharma
Resonance Health has been contracted by Sun Pharmaceutical Industries for a clinical trial in Australia, valued at AUD $13.775 million.